Introducing
The largest multi-modal data platform for early-stage cancer research
*Based on publicly available data
What real continuous response intelligence looks like.
Unlike other RWD built on single clinical encounters, MIIRA is multi-timepoint, linking an average of 9 longitudinal Signatera MRD timepoints per patient1 to native Altera WES/WTS* and clinico-genomic context, including:
- H & E
- Imaging
- Treatments and Procedures
- Clinical Outcomes
…across 450,000+ unique de-identified patient journeys for a truly complete and continuous view of cancer at both the molecular and clinical level.2
*or whole genome where available
Define your patient population before your trial does it for you.
All-Comer Population (IMvigor0103)
IMvigor010, an all-comer adjuvant study in MIBC, did not meet its primary DFS endpoint in the intent-to-treat population
In adjuvant and escalation settings, all-comer approaches risk diluting or obscuring treatment effects by including patients who do not need additional therapy.
Disease-free Survival (IMvigor0113)
IMvigor011 met its primary DFS and OS endpoints in ctDNA+ patients
Treatment on MRD (TOMR) approaches target the patients who may actually benefit from treatment initiation or escalation.
Use MIIRA to model TOMR and MRD-defined population scenarios well ahead of your trial to de-risk development decisions and identify patients with true unmet clinical needs.
Learn more about TOMR
New possibilities for clinical development and trials
Case Study – Curative-intent Trials
MRD-guided trial design
& patient matching
Identify MRD-guided patient populations for trial matching and enrollment, based on commercial Signatera data linked to real-world inclusion and exclusion criteria, to improve probability of trial success.
Read case study
Case Study – Metastatic Drug Development
Real-world comparator benchmarking for early-phase decision making
Generate regulatory-grade real-world control arms to benchmark against investigational therapies for earlier go-forward decisions.
Read case study
The difference is in the data
Largest multi-timepoint RWD
for early-stage cancers.
75%
of patients are first tested in the early-stage setting
Continuous response assessment across patient journey.
~3K
new recurrence/progression events per month
Always growing, always current.
40%
annual growth in MIIRA patients
Less bias. More reality.
70%
community oncology - where most cancer patients actually receive care
How to work with MIIRA
MIIRA Workspace
Explore cohorts and test feasibility on demand, with pre-built analytics and visualization
Data Licensing
License analysis-ready cohorts, full therapeutic areas, or the entire dataset
Custom Services
Partner with our in-house RWE and bioinformatics team to design, run, and publish custom analyses
Patient Matching
Identify patients eligible for MRD-guided trials based on Signatera results and real-world I/E criteria
Press Release
Webinar
Request a feasibility report
Talk with our team about cohort feasibility, licensing, and custom analytics with MIIRA RWD
* Indicates a required field
References
